No change on triple therapy: latest advice
A WORLDWIDE move to recommend quadruple therapy as first-line treatment for Helicobacter pylori infection is not yet warranted in Australia, experts say.
New Australian advice will recommend that triple therapy remain GPs’ first option here given recent data showing clarithromycin resistance is relatively low at 5–7%.
Clinical Associate Professor Peter Katelaris, co-author of Therapeutic Guidelines: Gastrointestinal (Version 5), expected later this month, said the push for quadruple therapy came from countries with high resistance.
A recent European study found rates of clarithromycin resistance as high as 23%.
Professor Katelaris, from Sydney’s Concord Hospital, said Australian research showed triple therapy was equally effective but better tolerated.
“For our GPs there is no reason to change choice of first-line therapy at present because of our low clarithromycin resistance rates,” he said.